DexCom, Inc. (NASDAQ:DXCM) a medical device firm will be discussing 2Q20 financial results with the investment community.on 28th July 2020 at 4:30 PM eastern time.
Those interested in listening to the conference call live via the Internet can visit www.dexcom.com
Earnings Expectation
DexCom, Inc. is reporting second quarter financial results on Tuesday 28th July 2020, after market close.
According to analysts surveyed by Thomson Reuters, DXCM is expected to report 2Q20 income of $ 0.35 per share from revenue of $ 415.74 million.
For the full year, analysts anticipate top line of $ 1799.51 million, while looking forward to income of $ 2.30 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 1,725.00 million ~ $ 1,775.00 million
Click Here For More Historical Outlooks Of DexCom, Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patients mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
